全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs

DOI: 10.4236/alc.2017.62002, PP. 13-35

Keywords: Patient-Reported Outcome, Chemotherapy, Quality of Life, Non-Small Cell Lung Cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Patient-reported outcomes (PROs) of quality of life (QOL) during chemotherapy involving lung cancer are very important for the medical staffs. Patients’ satisfaction and healthy changes were evaluated by the patient-self assessment. Materials and Methods: From July 2007 to April 2008, a total of 19 patients received chemotherapy. The QOL data were collected by using the QOL questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) and the anti-aging QOL assessment (AA-QOL). The AA-QOL contained 51 items: 30 of physical and 21 of mental symptoms of the elderly and the aging population. The patients replied to the questions at two different times, i.e., at pre-chemotherapy (baseline) and at post-chemotherapy (2 weeks after the chemotherapy). Results: Regarding the hematological toxicities, for the grade 3/4 toxicities, there were 12 neutropenia (12/19, 63.2%) and 3 thrombocytopenia (3/19, 15.8%). For the grade 3 febrile neutropenia, there were 5 cases (5/19, 26.3%). Regarding the non-hematological toxicities, there was no grade 3 and grade 4 toxicities. Based on the outcomes of the QOL-ACD, the three items (“physical condition”, “social attitude”, and “overall QOL”) at post-chemotherapy became significantly worse compared to the baseline. Regarding the outcomes of the AA-QOL, 4 items of physical symptoms (“thirst”, “anorexia”, “early satiety”, and “diarrhea”) became significantly worse compared to the baseline. Regarding the mental symptoms, 2 items (“nothing to look forward in life” and “a sense of uselessness”) became significantly worse compared to the baseline. Conclusion: Regarding the PROs of the QOL during the chemotherapy term, both the physical and mental symptoms had become worse. To clarify the changes in the QOL during chemotherapy is very important for multidisciplinary teamwork, which should play the role of providing the appropriate cares and treatment as patient-support.

 References

[1]  Greenlee, R.T., Hill-Harmon, M.B., Murray, T. and Thun, M. (2001) Cancer Statistics, 2001. CA: A Cancer Journal for Clinicians, 51, 15-36.
https://doi.org/10.3322/canjclin.51.1.15
[2]  Parkin, D.M., Pisani, P. and Ferlay, J. (1985) Estimates of the Worldwide Incidence of Eighteen Major Cancers in 1985. International Journal of Cancer, 54, 594-606.
https://doi.org/10.1002/ijc.2910540413
[3]  Hori, M., Matsuda, T., Shibata, A., Katanoda, K., Sobue, T., Nishimoto, H., et al. (2015) Cancer Incidence and Incidence Rates in Japan in 2009: A Study of 32 Population-Based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Japanese Journal of Clinical Oncology, 45, 884-891.
https://doi.org/10.1093/jjco/hyv088
[4]  Grilli, R., Oxman, A.D. and Julian, J.A. (1993) Chemotherapy for Advanced Non-Small-Cell Lung Cancer: How Much Benefit Is Enough? Journal of Clinical Oncology, 11, 1866-1872.
https://doi.org/10.1200/JCO.1993.11.10.1866
[5]  Marino, P., Pampallona, S., Preatoni, A., Cantoni, A. and Invernizzi, F. (1994) Chemotherapy vs. Supportive Care in Advanced Non-Small-Cell Lung Cancer. Results of a Meta-Analysis of the Literature. Chest, 106, 861-865.
[6]  Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Data on Individual Patients from 52 Randomised Clinical Trials. BMJ, 311, 899-909.
https://doi.org/10.1136/bmj.311.7010.899
[7]  Souquet, P.J., Chauvin, F., Boissel, J.P., Cellerino, R., Cormier, Y., Ganz, P.A., Kaasa, S., Pater, J.L., Quoix, E., Rapp, E., et al. (1993) Polychemotherapy in Advanced Non Small Cell Lung Cancer: A Meta-Analysis. The Lancet, 342, 19-21.
https://doi.org/10.1016/0140-6736(93)91882-M
[8]  Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J. and Johnson, D.H., Eastern Cooperative Oncology Group (2002) Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 346, 92-98.
https://doi.org/10.1056/NEJMoa011954
[9]  Kubota, K., Nishiwaki, Y., Ohashi, Y., Saijo, N., Ohe, Y., Tamura, T., Negoro, S., Ariyoshi, Y., Nakagawa, K. and Fukuoka, M. (2004) The Four-Arm Cooperative Study (FACS) for Advanced Non-Small-Cell Lung Cancer (NSCLC). Proceeding of the American Society of Clinical Oncology, 22, 14S.
[10]  Gridelli, C. and Shepherd, F.A. (2005) Chemotherapy for Elderly Patients with Non-Small Cell Lung Cancer: A Review of the Evidence. Chest, 128, 947-957.
[11]  Keller, S.M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B.J., Perry, M.C., Livingston, R.B. and Johnson, D.H., Eastern Cooperative Oncology Group (2000) A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIA Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 343, 1217-1222.
https://doi.org/10.1056/NEJM200010263431703
[12]  Ichinose, Y., Tada, H., Koike, T., Nishizawa, N., Tsuchiya, R., Nagai, K., et al. (2001) A Randomized Phase III Trial of Postoperative Adjuvant Chemotherapy in Patients with Completely Resected Stage IIIA-N2 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group (JCOG) 9304 Trial. Proceedings of ASCO 2001, 20, Article ID: A1241.
[13]  Scagliotti, G.V., Fossati, R., Torri, V., Crinò, L., Giaccone, G., Silvano, G., Martelli, M., Clerici, M., Cognetti, F. and Tonato, M., Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators (2003) Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 95, 1453-1461.
https://doi.org/10.1093/jnci/djg059
[14]  Waller, D., Fairlamb, D.J., Gower, N, Milroy, R., Peake, M.D., Rudd, R.M., et al. (2003) The Big Lung Trial (BLT): Determining the Value of Cisplatin-Based Chemotherapy for All Patients with Non-Small Cell Lung Cancer (NSCLC). Preliminary Results in the Surgical Setting. Proceedings of ASCO 2003, 22, Article ID: A2543.
[15]  Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J.P. and Vansteenkiste, J., The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-Based Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 350, 351-360.
https://doi.org/10.1056/NEJMoa031644
[16]  (1995) The World Health Organization Quality of Life Assessment (WHOQOL): Position Paper from the World Health Organization. Social Science & Medicine, 41, 1403-1409.
[17]  Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B., de Haes, J.C., et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. Journal of the National Cancer Institute, 85, 365-376.
https://doi.org/10.1093/jnci/85.5.365
[18]  Bergman, B., Aaronson, N.K., Ahmedzai, S., Kaasa, S. and Sullivan, M. (1994) The EORTC QLQ-LC13: A Modular Supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for Use in Lung Cancer Clinical Trials. EORTC Study Group on Quality of Life. European Journal of Cancer, 30, 635-642.
https://doi.org/10.1016/0959-8049(94)90535-5
[19]  Giaccone, G., Splinter, T.A,, Debruyne, C., Kho, G.S., Lianes, P., van Zandwijk, N., Pennucci, M.C., Scagliotti, G., van Meerbeeck, J., van Hoesel, Q., Curran, D., Sahmoud, T. and Postmus, P.E. (1998) Randomized Study of Paclitaxel-Cisplatin versus Cisplatin-Teniposide in Patients with Advanced Non-Small-Cell Lung Cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of Clinical Oncology, 16, 2133-2141.
https://doi.org/10.1200/jco.1998.16.6.2133
[20]  Helsing, M., Bergman, B., Thaning, L. and Hero, U. (1998) Quality of Life and Survival in Patients with Advanced Non-Small Cell Lung Cancer Receiving Supportive Care plus Chemotherapy with Carboplatin and Etoposide or Supportive Care Only. A Multicentre Randomised Phase III Trial. European Journal of Cancer, 34, 1036-1044.
https://doi.org/10.1016/S0959-8049(97)10122-8
[21]  Cullen, M.H., Billingham, L.J., Woodroffe, C.M., Chetiyawardana, A.D., Gower, N.H., Joshi, R., Ferry, D.R., Rudd, R.M., Spiro, S.G., Cook, J.E., Trask, C., Bessell, E., Connolly, C.K., Tobias, J. and Souhami, R.L. (1999) Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life. Journal of Clinical Oncology, 17, 3188-3194.
https://doi.org/10.1200/jco.1999.17.10.3188
[22]  Crinò, L., Scagliotti, G.V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., Sassi, M., Barni, S., Ravaioli, A., Adamo, V., Portalone, L., Cruciani, G., Masotti, A., Ferrara, G., Gozzelino, F. and Tonato, M. (1999) Gemcitabine and Cisplatin versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project. Journal of Clinical Oncology, 17, 3522-3530.
[23]  Cardenal, F., López-Cabrerizo, M.P., Antón, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., García, M., Lianes, P., Montalar, J., Vadell, C., González-Larriba, J.L., Nguyen, B., Artal, A. and Rosell, R. (1999) Randomized Phase III Study of Gemcitabine-Cisplatin versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 17, 12-18.
https://doi.org/10.1200/JCO.1999.17.1.12
[24]  Roszkowski, K., Pluzanska, A., Krzakowski, M., Smith, A.P., Saigi, E., Aasebo, U., Parisi, A., Pham Tran, N., Olivares, R. and Berille, J. (2000) A Multicenter, Randomized, Phase III Study of Docetaxel plus Best Supportive Care versus Best Supportive Care in chemotherapy-Naive Patients with Metastatic or Non-Resectable Localized Non-Small Cell Lung Cancer (NSCLC). Lung Cancer, 27, 145-157.
https://doi.org/10.1016/S0169-5002(00)00094-5
[25]  Ayabe, T., Tomita, M., Nose, N., Asada, T. and Nakamura, K. (2017) Patient-Reported Outcomes of Surgery of Non-Small Cell Lung Cancer: Evaluation Based on the Questionnaires of Anti-Aging Quality of Life and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Surgical Science, 8, 203-219.
https://doi.org/10.4236/ss.2017.85024
[26]  Kurihara, M., Shimizu, H., Tsuboi, K., Kobayashi, K., Murakami, M., Eguchi, K. and Shimozuma, K. (1999) Development of Quality of Life Questionnaire in Japan: Quality of Life Assessment of Cancer Patients Receiving Chemotherapy. Psycho-Oncology, 8, 355-363.
https://doi.org/10.1002/(SICI)1099-1611(199907/08)8:4<355::AID-PON401>3.0.CO;2-I
[27]  Yonei, Y., Iwaita, Y., Muramatsu, K. and Mizuno, Y. (2005) The Anti-Aging Secrets of Japanese Executives. Anti-Aging Medical Research, 2, 61-69.
[28]  Sobin, L.H. and Fleming, I.D. (1997) TNM Classification of Malignant Tumors, Fifth Edition (1997). Cancer, 80, 1803-1804.
https://doi.org/10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9
[29]  Travis, W.D., Garg, K., Franklin, W.A., Wistuba, I.I., Sabloff, B., Noguchi, M., Kakinuma, R., Zakowski, M., Ginsberg, M., Padera, R., Jacobson, F., Johnson, B.E., Hirsch, F., Brambilla, E., Flieder, D.B., Geisinger, K.R., Thunnissen, F., Kerr, K., Yankelevitz, D., Franks, T.J., Galvin, J.R., Henderson, D.W., Nicholson, A.G., Hasleton, P.S., Roggli, V., Tsao, M.S., Cappuzzo, F. and Vazquez, M. (2006) Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 1, S13-S19.
https://doi.org/10.1016/S1556-0864(15)30004-6
[30]  Calvert, A.H., Newell, D.R., Gumbrell, L.A., O’Reilly, S., Burnell, M., Boxall, F.E., Siddik, Z.H., Judson, I.R., Gore, M.E. and Wiltshaw, E. (1989) Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. Journal of Clinical Oncology, 7, 1748-1756.
https://doi.org/10.1200/JCO.1989.7.11.1748
[31]  Cockcroft, D.W. and Gault, M.H. (1976) Prediction of Creatinine Clearance from Serum Creatinine. Nephron, 16, 31-41.
https://doi.org/10.1159/000180580
[32]  Matsumoto, T., Ohashi, Y., Morita, S., Kobayashi, K., Shibuya, M., Yamaji, Y., Eguchi, K., Fukuoka, M., Nagao, K., Nishiwaki, Y. and Niitani, H. (2002) The Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD): Validity and Reliability in Japanese Patients with Advanced Non-Small-Cell Lung Cancer. Quality of Life Research, 11, 483-493.
https://doi.org/10.1023/A:1015614505929
[33]  Jemal, A., Murray, T., Ward, E., et al. (2005) Cancer Statistics, 2005. CA: A Cancer Journal for Clinicians, 55, 10-30.
https://doi.org/10.3322/canjclin.55.1.10
[34]  Mountain, C. (1997) Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-1717.
[35]  Brown, J., Thorpe, H., Napp, V., Fairlamb, D.J., Gower, N.H., Milroy, R., Parmar, M.K., Rudd, R.M., Spiro, S.G., Stephens, R.J., Waller, D., West, P. and Peake, M.D. (2005) Assessment of Quality of Life in the Supportive Care Setting of the Big Lung Trial in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 23, 7417-7427.
https://doi.org/10.1200/jco.2005.09.158
[36]  Spiro, S.G., Rudd, R.M., Souhami, R.L., Brown, J., Fairlamb, D.J., Gower, N.H., Maslove, L., Milroy, R., Napp, V., Parmar, M.K., Peake, M.D., Stephens, R.J., Thorpe, H., Waller, D.A. and West, P., Big Lung Trial Participants (2004) Chemotherapy versus Supportive Care in Advanced Non-Small Cell Lung Cancer: Improved Survival without Detriment to Quality of Life. Thorax, 59, 828-836.
https://doi.org/10.1136/thx.2003.020164
[37]  Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M. and Johnson, D. (2000) Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated with Two Dose Levels of Paclitaxel Combined with Cisplatin versus Etoposide with Cisplatin: Results of an Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 18, 623-631.
https://doi.org/10.1200/jco.2000.18.3.623
[38]  Gatzemeier, U., von Pawel, J., Gottfried, M., ten Velde, G.P., Mattson, K., de Marinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A., Bogaerts, J. and Gallant, G. (2000) Phase III Comparative Study of High-Dose Cisplatin versus a Combination of Paclitaxel and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 18, 3390-3399.
https://doi.org/10.1200/jco.2000.18.19.3390
[39]  Kelly, K., Crowley, J., Bunn Jr., P.A., Presant, C.A., Grevstad, P.K., Moinpour, C.M., Ramsey, S.D., Wozniak, A.J., Weiss, G.R., Moore, D.F., Israel, V.K., Livingston, R.B. and Gandara, D.R. (2001) Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Vinorelbine plus Cisplatin in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial. Journal of Clinical Oncology, 19, 3210-3218.
https://doi.org/10.1200/jco.2001.19.13.3210
[40]  Manegold, C., Bergman, B., Chemaissani, A., Dornoff, W., Drings, P., Kellokumpu-Lehtinen, P., Liippo, K., Mattson, K., van Pawel, J., Ricci, S., Sederholm, C., Stahel, R.A., Wagenius, G., van Walree, N. and ten Bokkel-Huinink, W. (1997) Single-Agent Gemcitabine versus Cisplatin-Etoposide: Early Results of a Randomised Phase II Study in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Annals of Oncology, 8, 525-529.
https://doi.org/10.1023/A:1008207731111
[41]  Perng, R.P., Chen, Y.M., Ming-Liu, J., Tsai, C.M., Lin, W.C., Yang, K.Y. and Whang-Peng, J. (1997) Gemcitabine versus the Combination of Cisplatin and Etoposide in Patients with Inoperable Non-Small-Cell Lung Cancer in a Phase II Randomized Study. Journal of Clinical Oncology, 15, 2097-2102.
https://doi.org/10.1200/JCO.1997.15.5.2097
[42]  Sandler, A. and Ettinger, D.S. (1999) Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer. Oncologist, 4, 241-251.
[43]  Sederholm, C., Hillerdal, G., Lamberg, K., Kolbeck, K., Dufmats, M., Westberg, R. and Gawande, S.R. (2005) Phase III Trial of Gemcitabine plus Carboplatin versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group. Journal of Clinical Oncology, 23, 8380-8388.
https://doi.org/10.1200/jco.2005.01.2781
[44]  Vansteenkiste, J.F., Vandebroek, J.E., Nackaerts, K.L., Weynants, P., Valcke, Y.J., Verresen, D.A., Devogelaere, R.C., Marien, S.A., Humblet, Y.P. and Dams, N.L., Leuven Lung Cancer Group. (2001) Clinical-Benefit Response in Advanced Non-Small-Cell Lung Cancer: A Multicentre Prospective Randomised Phase III Study of Single Agent Gemcitabine versus Cisplatin-Vindesine. Annals of Oncology, 12, 1221-1230.
https://doi.org/10.1023/A:1012208711013
[45]  Georgoulias, V., Papadakis, E., Alexopoulos, A., Tsiafaki, X., Rapti, A., Veslemes, M., Palamidas, P. and Vlachonikolis, I., Greek Oncology Cooperative Group (GOCG) for Lung Cancer (2001) Platinum-Based and Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Randomised Multicentre Trial. The Lancet, 357, 1478-1484.
https://doi.org/10.1016/S0140-6736(00)04644-4
[46]  Georgoulias, V., Ardavanis, A., Tsiafaki, X., Agelidou, A., Mixalopoulou, P., Anagnostopoulou, O., Ziotopoulos, P., Toubis, M., Syrigos, K., Samaras, N., Polyzos, A., Christou, A., Kakolyris, S., Kouroussis, C., Androulakis, N., Samonis, G. and Chatzidaki, D. (2005) Vinorelbine plus Cisplatin versus Docetaxel plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial. Journal of Clinical Oncology, 23, 2937-2945.
https://doi.org/10.1200/jco.2005.04.016
[47]  Gridelli, C., Gallo, C., Shepherd, F.A., Illiano, A., Piantedosi, F., Robbiati, S.F., Manzione, L., Barbera, S., Frontini, L., Veltri, E., Findlay, B., Cigolari, S., Myers, R., Ianniello, G.P., Gebbia, V., Gasparini, G., Fava, S., Hirsh, V., Bezjak, A., Seymour, L. and Perrone, F. (2003) Gemcitabine plus Vinorelbine Compared with Cisplatin plus Vinorelbine or Cisplatin plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 21, 3025-3034.
https://doi.org/10.1200/jco.2003.06.099
[48]  Kosmidis, P., Mylonakis, N., Nicolaides, C., Kalophonos, C., Samantas, E., Boukovinas, J., Fountzilas, G., Skarlos, D., Economopoulos, T., Tsavdaridis, D., Papakostas, P., Bacoyiannis, C. and Dimopoulos, M. (2002) Paclitaxel plus Carboplatin Versus Gemcitabine plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial. Journal of Clinical Oncology, 20, 3578-3585.
https://doi.org/10.1200/jco.2002.12.112
[49]  Smit, E.F., van Meerbeeck, J.P., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., Neymark, N. and Giaccone, G. (2003) Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. Journal of Clinical Oncology, 21, 3909-3917.
https://doi.org/10.1200/JCO.2003.03.195
[50]  Buccheri, G.F., Ferrigno, D., Curcio, A., Vola, F. and Rosso, A. (1989) Continuation of Chemotherapy versus Supportive Care Alone in Patients with Inoperable Non-Small Cell Lung Cancer and Stable Disease after Two or Three Cycles of MACC. Results of a Randomized Prospective Study. Cancer, 63, 428-432.
https://doi.org/10.1002/1097-0142(19890201)63:3<428::AID-CNCR2820630305>3.0.CO;2-V
[51]  Smith, I.E., O’Brien, M.E., Talbot, D.C., Nicolson, M.C., Mansi, J.L., Hickish, T.F., Norton, A. and Ashley, S. (2001) Duration of Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Randomized Trial of Three versus Six Courses of Mitomycin, Vinblastine, and Cisplatin. Journal of Clinical Oncology, 19, 1336-1343.
https://doi.org/10.1200/jco.2001.19.5.1336
[52]  Socinski, M.A., Schell, M.J., Peterman, A., Bakri, K., Yates, S., Gitten, R., Unger, P., Lee, J., Lee, J.H., Tynan, M., Moore, M. and Kies, M.S. (2002) Phase III Trial Comparing a Defined Duration of Therapy versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 20, 1335-1343.
[53]  Bezjak, A., Lee, C.W., Ding, K., Brundage, M., Winton, T., Graham, B., Whitehead, M., Johnson, D.H., Livingston, R.B., Seymour, L. and Shepherd, F.A. (2008) Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non-Small-Cell Lung Cancer: Results from a Randomized Trial, JBR.10. Journal of Clinical Oncology, 26, 5052-5059.
https://doi.org/10.1200/JCO.2007.12.6094
[54]  NSCLC Meta-Analyses Collaborative Group, Arriagada, R., Auperin, A., Burdett, S., Higgins, J.P., Johnson, D.H., Le Chevalier, T., Le Pechoux, C., Parmar, M.K., Pignon, J.P., Souhami, R.L., et al. (2010) Adjuvant Chemotherapy, with or without Postoperative Radiotherapy, in Operable Non-Small-Cell Lung Cancer: Two Meta-Analyses of Individual Patient Data. The Lancet, 375, 1267-1277.
https://doi.org/10.1016/S0140-6736(10)60059-1
[55]  Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., Fry, W., Bethune, D., Ayoub, J., Ding, K., Seymour, L., Graham, B., Tsao, M.S., Gandara, D., Kesler, K., Demmy, T. and Shepherd, F., National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators (2005) Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 352, 2589-2597.
https://doi.org/10.1056/NEJMoa043623
[56]  Douillard, J.Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J.L., Grodzki, T., Pereira, J.R., Le Groumellec, A., Lorusso, V., et al. (2006) Adjuvant Vinorelbine plus Cisplatin versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial. The Lancet Oncology, 7, 719-727.
https://doi.org/10.1016/S1470-2045(06)70804-X
[57]  Zatloukal, P., Petruzelka, L., Zemanová, M., Kolek, V., Skricková, J., Pesek, M., Fojtu, H., Grygárková, I., Sixtová, D., Roubec, J., et al. (2003) Gemcitabine plus Cisplatin vs. Gemcitabine plus Carboplatin in Stage IIIb and IV Non-Small Cell Lung Cancer: A Phase III Randomized Trial. Lung Cancer, 41, 321-331.
https://doi.org/10.1016/S0169-5002(03)00233-2
[58]  Rocchi, P., Mattioli, C., Rocchi, M.B., Mattioli, R., Lippe, P., Trivisonne, R., Buzzi, F., De Signoribus, G., Tuveri, G., Rossi, G., et al., (2003) Randomized, Multicenter, Phase II Study of Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer. Lung Cancer, 41, 81-89.
https://doi.org/10.1016/S0169-5002(03)00140-5
[59]  Hirabayashi, M., Endoh, K., Teramachi, M., Okuda, M., Yamaguchi, K., Fukuda, K., Tokuhisa, H., Kagioka, H., Nakai, N. and Nakade, M. (2004) Phase II Study of Carboplatin and Weekly Paclitaxel Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Kansai Clinical Oncology Group Study. Lung Cancer, 44, 355-362.
https://doi.org/10.1016/j.lungcan.2003.12.001
[60]  Ayabe, T., Tomita, M., Chosa, E., Ikenoue, M., Shirasaki, Y. and Nakamura, K. (2014) Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 5, 281-296.
https://doi.org/10.4236/jct.2014.53035
[61]  Ayabe, T., Tomita, M. and Nakamura, K. (2013) Adjuvant Chemotherapy of Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with Resected Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 4, 15-23.
https://doi.org/10.4236/jct.2013.48A003
[62]  United Kingdom Department of Health (2007) Guidance on the Routine Collection of Patient Reported Outcome Measures (PROMs).
[63]  Rogers, S.N. (2010) Quality of Life Perspectives in Patients with Oral Cancer. Oral Oncology, 46, 445-447.
https://doi.org/10.1016/j.oraloncology.2010.02.021
[64]  Efficace, F., Bottomley, A., Coens, C., Van Steen, K., Conroy, T., Schoffski, P., Schmoll, H., Van Cutsem, E. and Kohne, C.H. (2006) Does a Patient’s Self-Reported Health-Related Quality of Life Predict Survival beyond Key Biomedical Data in Advanced Colorectal Cancer? European Journal of Cancer, 42, 42-49.
[65]  Deshpande, P.R., Rajan, S., Sudeepthi, B.L. and Abdul Nazir, C.P. (2011) Patient-Reported Outcomes: A New Era in Clinical Research. Perspectives in Clinical Research, 2, 137-144.
https://doi.org/10.4103/2229-3485.86879
[66]  Kozma, C.M., Reeder, C.E. and Schulz, R.M. (1993) Economic, Clinical, and Humanistic Outcomes: A Planning Model for Pharmacoeconomic Research. Clinical Therapeutics, 15, 1121-1132; Discussion 1120.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133